相关实验视频

Updated: Feb 14, 2026

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

动脉样硬化疾病中长非编码RNA的细胞机制和治疗向

Rasha Abu-Khudir¹, Ahmed S Doghish^2,3, Mai A Abd-Elmawla⁴

¹Department of Chemistry, College of Science, King Faisal University, Hofuf, Saudi Arabia.

|February 13, 2026

概括

长非编码RNAs (lncRNAs) 是动脉样硬化发展和进展的关键参与者. 准这些分子为早期检测和治疗动脉样硬化的疾病提供了有前途的新治疗策略.

科学领域:

分子生物学分子生物学
心血管研究研究心血管研究
遗传学是一个遗传学.

背景情况:

动脉样硬化需要早期检测生物标志物和治疗点,以防止不稳定的斑块形成.
长非编码RNAs (lncRNAs) 具有独特的特征,使它们成为有前途的疾病生物标志物.
lncRNAs在与动脉样硬化相关的各种生物过程中发挥着重要作用.

研究的目的:

审查 lncRNAs 在动脉样硬化病原,诊断和预后中的作用.
突出针对动脉样硬化的lncRNAs的治疗干预措施.
阐明在动脉样硬化发展中的lncRNA调节机制.

主要方法:

关于动脉样硬化中 lncRNAs 的最新研究的文献综述.
分析lncRNA参与内皮功能障碍,脂质代谢和斑块稳定性的分析.
检查 lncRNA 在诊断和预后中的作用,以及治疗向策略.

主要成果:

lncRNAs通过涉及NEAT1,lincRNA-p21,MALAT1,H19,GAS5,MEG3,HOTAIR和TUG1.1的机制显著影响动脉样硬化进展.
特定的lncRNAs如APPAT,MALAT1,MIAT,SOX2-OT,HIF1A-AS1,IncRNA-ATB,PVT1,NORAD,HOTAIR,H19,LIPCAR和DANCR都涉及到诊断和预后. 这种类型的lncRNAs通常被认为是最常见的.
通过TNF-α,JAK/STAT,IFN-γ,ROCK1,AP1,NF-κB和PI3K/AKT/mTOR等途径对lncRNA的治疗向提供了新的基于RNA的治疗机会.

结论:

lncRNAs是动脉样硬化中基因表达和细胞过程的关键调节者.
针对 lncRNAs 为开发动脉样硬化疾病的诊断和治疗方法提供了新的前沿.
对lncRNA机制的进一步研究可以导致对动脉样硬化的有效早期干预.

关键词:

动脉样硬化动脉样硬化生物标志物生物标志物诊断诊断诊断诊断诊断诊断在ncRNA中,我们可以治疗疗法治疗疗法治疗疗法

更多相关视频

Isolation of Small Noncoding RNAs from Human Serum

Isolation of Small Noncoding RNAs from Human Serum

Published on: June 19, 2014

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Published on: December 1, 2023

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

piRNA - Piwi-interacting RNAs

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...

Small interfering RNAs (siRNA)

Small interfering RNAs (siRNA)

Therapeutic Index

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...